创伤性胸主动脉损伤的胸主动脉腔内修复术的应用及疗效的全国趋势。
National trends in utilization and outcome of thoracic endovascular aortic repair for traumatic thoracic aortic injuries.
作者信息
Ultee Klaas H J, Soden Peter A, Chien Victor, Bensley Rodney P, Zettervall Sara L, Verhagen Hence J M, Schermerhorn Marc L
机构信息
Division of Vascular and Endovascular Surgery, Department of Surgery, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Mass; Department of Vascular Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands.
Division of Vascular and Endovascular Surgery, Department of Surgery, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Mass.
出版信息
J Vasc Surg. 2016 May;63(5):1232-1239.e1. doi: 10.1016/j.jvs.2015.11.034. Epub 2016 Jan 6.
BACKGROUND
Endovascular repair of traumatic thoracic aortic injuries (TTAI) is an alternative to conventional open surgical repair. Single-institution studies have shown a survival benefit with thoracic endovascular aortic repair (TEVAR), but whether this is being realized nationally is not clear. The purpose of our study was to document trends in the increase in use of TEVAR and its effect on outcomes of TTAI nationally.
METHODS
Patients admitted with a TTAI between 2005 and 2011 were identified in the National Inpatient Sample. Patients were grouped by treatment into TEVAR, open repair, or nonoperative management. Primary outcomes were relative use over time and in-hospital mortality. Secondary outcomes included postoperative complications and length of stay. Multivariable logistic regression was performed to identify independent predictors of mortality.
RESULTS
Included were 8384 patients, with 2492 (29.7%) undergoing TEVAR, 848 (10.1%) open repair, and 5044 (60.2%) managed nonoperatively. TEVAR became the dominant treatment option for TTAI during the study period, starting at 6.5% of interventions in 2005 and accounting for 86.5% of interventions in 2011 (P < .001). Nonoperative management declined concurrently with the widespread of adoption TEVAR (79.8% to 53.7%; P < .001). In-hospital mortality after TEVAR decreased during the study period from 33.3% in 2005 to 4.9% in 2011 (P < .001), and an increase in mortality was observed for open repair from 13.9% to 19.2% (P < .001). Procedural mortality (TEVAR or open repair) decreased from 14.9% to 6.7% (P < .001), and mortality after any TTAI admission declined from 24.5% to 13.3% during the study period (P < .001). In addition to lower mortality, TEVAR was followed by fewer cardiac complications (4.1% vs 8.5%; P < .001), respiratory complications (47.5% vs 54.8%; P < .001), and shorter length of stay (18.4 vs 20.2 days; P = .012) compared with open repair. In adjusted mortality analyses, open repair proved to be associated with twice the mortality risk compared with TEVAR (odds ratio, 2.1; 95% confidence interval, 1.6-2.7), and nonoperative management was associated with more than a fourfold increase in mortality (odds ratio, 4.5; 95% confidence interval, 3.8-5.3).
CONCLUSIONS
TEVAR is now the dominant surgical approach in TTAI, with substantial perioperative morbidity and mortality benefits over open aortic repair. Overall mortality after admission for TTAI has declined, which is most likely the result of the replacement of open repair by TEVAR as well as the broadened eligibility for operative repair.
背景
创伤性胸主动脉损伤(TTAI)的血管腔内修复是传统开放手术修复的一种替代方法。单机构研究表明,胸主动脉腔内修复术(TEVAR)可提高生存率,但在全国范围内是否如此尚不清楚。我们研究的目的是记录全国范围内TEVAR使用增加的趋势及其对TTAI治疗结果的影响。
方法
在国家住院患者样本中确定2005年至2011年期间因TTAI入院的患者。患者按治疗方式分为TEVAR组、开放修复组或非手术治疗组。主要结局是随时间推移的相对使用情况和住院死亡率。次要结局包括术后并发症和住院时间。进行多变量逻辑回归以确定死亡率的独立预测因素。
结果
纳入8384例患者,其中2492例(29.7%)接受TEVAR治疗,848例(10.1%)接受开放修复,5044例(60.2%)接受非手术治疗。在研究期间,TEVAR成为TTAI的主要治疗选择,从2005年占干预措施的6.5%增至2011年的86.5%(P <.001)。随着TEVAR的广泛应用,非手术治疗同时减少(从79.8%降至53.7%;P <.001)。研究期间,TEVAR后的住院死亡率从2005年的33.3%降至2011年的4.9%(P <.001),开放修复的死亡率从13.9%增至19.2%(P <.001)。手术死亡率(TEVAR或开放修复)从14.9%降至6.7%(P <.001),研究期间任何TTAI入院后的死亡率从24.5%降至13.3%(P <.001)。与开放修复相比,TEVAR不仅死亡率更低,心脏并发症也更少(4.1%对8.5%;P <.001)、呼吸并发症更少(47.5%对54.8%;P <.001),住院时间更短(18.4天对20.2天;P =.012)。在调整死亡率分析中,与TEVAR相比,开放修复的死亡风险高出两倍(比值比,2.1;95%置信区间,1.6 - 2.7),非手术治疗的死亡风险增加超过四倍(比值比,4.5;95%置信区间,3.8 - 5.3)。
结论
TEVAR现在是TTAI的主要手术方法,与开放主动脉修复相比,围手术期发病率和死亡率有显著益处。TTAI入院后的总体死亡率有所下降,这很可能是TEVAR取代开放修复以及手术修复适应证扩大的结果。